Over $1.00 The company recently announced that preliminary testing on human subjects showed that its Beta prototype breathalyzer is capable of detecting THC in real-time in subjects that smoked THC cigarettes. In addition to detecting THC, the device detected 11-hydroxy-delta-9-tetrahydrocannabinol, delta-9-carboxy-tetrahydrocannabinol, and three other cannabinoids related to cannabigerol that could be valuable to law enforcement.
The company plans to further test its Beta and Beta 2.0 prototypes over the coming weeks, where it will calibrate decay signal intensities with a refined breath collection component. The goal is to enable the breakthrough device to zero in on impairment with 'recency of use' like no other device on the market. With a first-mover advantage, the company could rapidly build market share in both the United States and Canada and globally.